Friday, 22 June 2012

Phrixus Pharmaceuticals, Inc. Announces $623,000 in NIH Funding for Its Program in Duchenne Muscular Dystrophy

Phrixus Pharmaceuticals, Inc. Announces $623,000 in NIH Funding for Its Program in Duchenne Muscular Dystrophy: Phrixus Pharmaceuticals, Inc., a clinical-stage, specialty pharmaceutical company focused on innovative therapies for Duchenne muscular dystrophy (DMD) and heart failure, today announced that it has received an SBIR Phase 1 award for $623,000 from the National Institutes of Health (NIH) for its grant application titled "Treatment of Muscular Dystrophy-Associated Dilated Cardiomyopathy with P-188."
"This funding constitutes validation for the potential utility of Carmeseal in DMD. We expect that it will allow us to extend administration of Carmeseal to a new, clinically relevant route of administration, subcutaneous delivery," said Thomas A. Collet, president and CEO.

No comments:

Post a comment